Skip to content

Rheumatoid arthritis — conventional DMARDs

TL;DR — Methotrexate is the conventional synthetic DMARD anchor because it is effective, inexpensive, dose-adjustable, and compatible with every major biologic/targeted class. Guidelines generally start methotrexate promptly, titrate it to an effective dose, add folate, and use subcutaneous delivery before declaring intolerance or inadequate response (Fraenkel 2021, PMID 34101376; Smolen 2023, PMID 36357155). Leflunomide and sulfasalazine are principal alternatives; hydroxychloroquine has lower structural potency and is best suited to selected low-activity or combination contexts. Combination conventional therapy can approach biologic efficacy in some strategy trials but toxicity and treatment burden differ (van Vollenhoven 2009, PMID 19665644). Glucocorticoids can bridge slow DMARD onset but cumulative infection, bone, metabolic and cardiovascular harms make rapid taper a core goal.

Comparative matrix

Drug Typical role Key monitoring Major cautions
Methotrexate Preferred anchor; mono- or combination therapy CBC, liver, renal; symptoms Pregnancy, liver disease, cytopenia, renal impairment, interactions
Leflunomide Alternative anchor CBC, liver, blood pressure Pregnancy; long half-life; hepatotoxicity
Sulfasalazine Alternative/combination; pregnancy-compatible in many contexts CBC, liver; hypersensitivity Sulfa reactions, cytopenia, reversible male infertility
Hydroxychloroquine Mild disease or combination Weight-based dose and retinal screening Retinopathy; rare cardiomyopathy/myopathy
Glucocorticoids Short bridge or flare rescue Dose, duration, glucose, bone, infection Cumulative toxicity; not a substitute for DMARD control

Methotrexate optimization

Methotrexate should not be labeled a failure after a low oral dose and short exposure unless toxicity requires cessation. ACR recommends titration to at least 15 mg/week within four to six weeks, with split oral dosing, folate, or subcutaneous administration as options for intolerance or inadequate effect (Fraenkel 2021, PMID 34101376).

Optimization step Rationale
Verify weekly—not daily—dosing Prevents catastrophic medication error
Folic/folinic supplementation Reduces mucosal and laboratory toxicity
Escalate dose promptly Avoids prolonged ineffective exposure
Split oral dose Can improve absorption/tolerability
Switch to subcutaneous Improves bioavailability at higher doses and may reduce GI effects
Check adherence and interactions Apparent failure may be delivery failure

A systematic review describes gastrointestinal and hepatic abnormalities as common and serious marrow, lung or other toxicity as less frequent (Wang 2018, PMID 30243154). Methotrexate pneumonitis is distinct from chronic RA-ILD; new dyspnea, cough, fever, hypoxemia or diffuse infiltrates require prompt reassessment rather than assumption of disease progression.

Monotherapy versus combinations

A Cochrane network meta-analysis compared methotrexate alone and combinations across DMARD-naive and inadequate-response populations; benefits and harms depend on prior exposure and comparator (Hazlewood 2016, PMID 27102806). An earlier review of 19 trials and 2,025 patients found combination conclusions differed between DMARD-naive and inadequate-response strata (Katchamart 2009, PMID 19054823).

SWEFOT began methotrexate in early RA and randomized inadequate responders to infliximab or sulfasalazine plus hydroxychloroquine; infliximab produced faster/better one-year responses, while longer-term and cost considerations narrowed the strategic contrast (van Vollenhoven 2009, PMID 19665644). FIN-RACo established that early conventional combination therapy can reduce damage (Korpela 2004, PMID 15248204).

Drug-specific evidence and cautions

Leflunomide

Leflunomide inhibits pyrimidine synthesis and can substitute for methotrexate. Long persistence of its active metabolite makes cholestyramine washout relevant for severe toxicity or pregnancy planning. Combining leflunomide with methotrexate may improve control but increases laboratory monitoring and liver-risk concern.

Sulfasalazine

Sulfasalazine is established for peripheral inflammatory arthritis and is part of “triple therapy.” Slow titration can reduce gastrointestinal intolerance. CBC and liver surveillance address cytopenia and hepatotoxicity.

Hydroxychloroquine

Hydroxychloroquine is not an adequate sole agent for high-activity erosive RA. Its role is selected low-activity disease or combination therapy. Retinal toxicity risk depends on dose relative to actual body weight, duration, kidney function and concurrent retinal risk; screening is mandatory.

Glucocorticoid bridge

EULAR 2022 allows short-term glucocorticoids with initial conventional therapy but emphasizes discontinuation as rapidly as clinically feasible (Smolen 2023, PMID 36357155). ACR 2021 conditionally recommends starting a conventional DMARD without longer-term glucocorticoids because harm often outweighs benefit (Fraenkel 2021, PMID 34101376).

Benefit Counterweight
Rapid symptom and swelling relief Infection risk
Short-term functional recovery Osteoporosis/fracture
May suppress early radiographic progression Diabetes, hypertension, weight gain
Buys time for DMARD onset Adrenal suppression and difficult withdrawal
Intra-articular targeting Septic-joint exclusion required

CAMERA II and other early-RA trials support disease-modifying effects of low-dose glucocorticoid addition, but this does not erase cumulative toxicity (Bijlsma 2015, PMID 26457916).

Monitoring as a treatment system

Baseline evaluation includes CBC, hepatic and renal function, pregnancy considerations, infection risk and vaccination status. Subsequent frequency depends on drug, dose, stability, comorbidity and concomitant medicines. Laboratory surveillance cannot replace symptom review: oral ulcers, breathlessness, rash, infection and neurologic symptoms may precede scheduled tests.

Landmark comparative estimates

Decision Quantified evidence Practical inference
Methotrexate starting dose and route A systematic review of 38 publications found that starting at 15 mg/week orally and escalating by 5 mg/month to 25–30 mg/week balanced efficacy and tolerability; subcutaneous 15 mg/week was more efficacious than oral dosing in early RA but caused more toxicity withdrawals (Visser 2009, PMID 19033290; Goodman 2015, PMID 25536122). Optimize dose, adherence, folate, and route before declaring methotrexate failure.
Triple therapy versus TNF inhibition after methotrexate RACAT randomized 353 patients: DAS28 change was −2.1 with triple therapy and −2.3 with etanercept–methotrexate; the upper 95% confidence limit for the difference was 0.41, below the 0.6 noninferiority margin (O'Dell 2013, PMID 23755969). A lower-cost conventional sequence can deliver similar clinical benefit in an appropriate patient.
Immediate versus step-up combination In TEAR, immediate combinations improved DAS28 sooner, but weeks 48–102 outcomes did not differ from step-up; etanercept–methotrexate had less radiographic change than triple therapy at week 102 (0.64 vs 1.69 units; p=0.047) (Moreland 2012, PMID 22508468). Earlier symptom control and small structural differences must be weighed against cost and overtreatment.
Glucocorticoid bridge in low-risk early RA CareRA remission at week 16 was 65.1% with methotrexate plus step-down prednisone versus 46.8% with methotrexate step-up (p=0.081); HAQ=0 occurred in 51.2% versus 23.4% (p=0.006) (Verschueren 2015, PMID 25889222). Short-term benefit is plausible, but the small trial did not establish the remission difference conclusively.
High- or low-dose bridge versus placebo In 395 patients, one-year Sharp-score change was 1.0, 1.1 and 1.1; high-dose versus placebo difference −0.04 (95% CI −0.5 to 0.4). Week-12 DAS28 improved, but week-52 activity did not differ (Krause 2022, PMID 35643951). Rapid symptom control does not necessarily translate into structural benefit; minimize cumulative exposure.

The controversy is not “methotrexate or biologic” in isolation. It is whether a health system can deliver fast escalation, monitoring, and switching. Cost-effectiveness analysis of TEAR favored triple therapy over initial etanercept under the modeled price structure, but the result is price- and jurisdiction-sensitive (Jalal 2016, PMID 27015606). Conventional drugs remain active strategy components, not merely prerequisites imposed before advanced therapy.

Evidence map

This map adds directly adjacent evidence used to bound interpretation. Inclusion means the record informs this topic or a tightly linked decision; it does not imply that every study supports every conclusion on the page.

Adjacent evidence Relevance to this page
Grigor C, et al. TICORA tight-control trial. Lancet. 2004. (PMID 15262104) Adjacent evidence from classification-and-diagnosis.md, clinical-trials-landscape.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md, treat-to-target-and-remission.md
Studenic P, et al. 2022 ACR/EULAR RA remission criteria revision. Arthritis Rheumatol. 2023. (PMID 36274193) Adjacent evidence from classification-and-diagnosis.md, epidemiology-and-burden.md, overview.md, treat-to-target-and-remission.md
Messelink MA, et al. Best target in a treat-to-target strategy in RA. Ann Rheum Dis. 2023. (PMID 37116986) Adjacent evidence from treat-to-target-and-remission.md
Mandl P, et al. Imaging for treat to target in RA. Rheumatology. 2019. (PMID 31518423) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md, treat-to-target-and-remission.md
Michaud K, et al. Systematic literature review of residual symptoms and unmet need in RA. Arthritis Care Res. 2021. (PMID 32619340) Adjacent evidence from epidemiology-and-burden.md, patient-experience-and-advocacy.md, treat-to-target-and-remission.md
Tascilar K, et al. RETRO tapering and stopping trial. Lancet Rheumatol. 2021. (PMID 38297524) Adjacent evidence from clinical-trials-landscape.md, treat-to-target-and-remission.md
Haschka J, et al. Relapse rates tapering or stopping antirheumatic therapy. Ann Rheum Dis. 2016. (PMID 25660991) Adjacent evidence from treat-to-target-and-remission.md
van Mulligen E, et al. TARA two-year tapering trial. Ann Rheum Dis. 2020. (PMID 32482645) Adjacent evidence from clinical-trials-landscape.md, treat-to-target-and-remission.md
Rivellese F, et al. Synovial biopsy biomarker analysis of R4RA. Nat Med. 2022. (PMID 35589854) Adjacent evidence from biologic-dmards.md, biomarkers-and-tissue-precision.md, clinical-trials-landscape.md, genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md, treat-to-target-and-remission.md
Kerschbaumer A, et al. DMARD efficacy review informing EULAR 2022. Ann Rheum Dis. 2023. (PMID 36368906) Adjacent evidence from classification-and-diagnosis.md, epidemiology-and-burden.md, guidelines.md, overview.md, treat-to-target-and-remission.md
England BR, et al. 2022 ACR guideline for exercise, rehabilitation, diet and integrative interventions in RA. Arthritis Rheumatol. 2023. (PMID 37227116) Adjacent evidence from guidelines.md, treat-to-target-and-remission.md
Peter WF, et al. Clinical practice guideline for physical therapist management of RA. Phys Ther. 2021. (PMID 34003240) Adjacent evidence from guidelines.md, treat-to-target-and-remission.md
Nagy G, et al. EULAR points to consider for management of difficult-to-treat RA. Ann Rheum Dis. 2022. (PMID 34407926) Adjacent evidence from classification-and-diagnosis.md, difficult-to-treat-and-refractory-ra.md, guidelines.md, treat-to-target-and-remission.md
Saavedra AA, et al. RA-ILD treatment: appraisal of 2023 ACR/CHEST guideline. 2025. (PMID 39822854) Adjacent evidence from guidelines.md, ra-associated-interstitial-lung-disease.md, treat-to-target-and-remission.md
Fautrel B, et al. 2024 French Society recommendations for RA diagnosis and management. 2024. (PMID 39389412) Adjacent evidence from guidelines.md, treat-to-target-and-remission.md
Abud-Mendoza C, et al. Mexican College of Rheumatology RA guideline 2023. 2024. (PMID 38796394) Adjacent evidence from guidelines.md, treat-to-target-and-remission.md
Harigai M, et al. 2024 Japan College of Rheumatology RA guideline update. 2025. (PMID 39820350) Adjacent evidence from guidelines.md, treat-to-target-and-remission.md
Conley B, et al. Core recommendations for RA care: systematic review of guidelines. 2023. (PMID 37291382) Adjacent evidence from guidelines.md, treat-to-target-and-remission.md
Ytterberg SR, et al. Cardiovascular and cancer risk with tofacitinib. N Engl J Med. 2022. (PMID 35081280) Adjacent evidence from classification-and-diagnosis.md, epidemiology-and-burden.md, extra-articular-and-comorbid-disease.md, guidelines.md, jak-inhibitors-and-targeted-therapy.md, overview.md, red-flags-and-safety-concerns.md, treat-to-target-and-remission.md
Nagy G, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021. (PMID 33004335) Adjacent evidence from classification-and-diagnosis.md, difficult-to-treat-and-refractory-ra.md, epidemiology-and-burden.md, overview.md, treat-to-target-and-remission.md
Buch MH, et al. Persistent inflammatory and non-inflammatory mechanisms in refractory RA. Nat Rev Rheumatol. 2021. (PMID 33293696) Adjacent evidence from classification-and-diagnosis.md, difficult-to-treat-and-refractory-ra.md, treat-to-target-and-remission.md
Evidence-map records are listed in full below and were live-retrieved from PubMed in this build session.

Open questions

  • Which patients gain enough from initial triple therapy to justify its pill and monitoring burden?
  • What is the safest effective glucocorticoid bridge duration in modern rapid-escalation care?
  • Can pharmacogenetics or metabolite monitoring identify methotrexate responders? (Ling 2020, PMID 31849277)
  • Does early subcutaneous rather than oral methotrexate improve long-term target attainment?
  • How should methotrexate be positioned when RA-ILD is already present?

References

  1. Fraenkel L, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73:1108-1123. PMID 34101376
  2. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3-18. PMID 36357155
  3. van Vollenhoven RF, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009;374:459-66. PMID 19665644
  4. Wang W, et al. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur J Med Chem. 2018;158:502-516. PMID 30243154
  5. Hazlewood GS, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ. 2016;353:i1777. PMID 27102806
  6. Katchamart W, et al. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2009;68:1105-12. PMID 19054823
  7. Korpela M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004;50:2072-81. PMID 15248204
  8. Bijlsma JW, et al. Glucocorticoids in the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2015;33:S34-6. PMID 26457916
  9. Visser K, et al. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68:1094-9. PMID 19033290
  10. Goodman SM, et al. Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. Clin Exp Rheumatol. 2015;33:272-8. PMID 25536122
  11. O'Dell JR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369:307-18. PMID 23755969
  12. Moreland LW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012;64:2824-35. PMID 22508468
  13. Verschueren P, et al. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther. 2015;17:97. PMID 25889222
  14. Krause D, et al. The Efficacy of Short-Term Bridging Strategies With High- and Low-Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Rheumatol. 2022;74:1628-1637. PMID 35643951
  15. Jalal H, et al. Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016;68:1751-1757. PMID 27015606
  16. Grigor C, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-9. PMID 15262104
  17. Studenic P, et al. American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision. Arthritis Rheumatol. 2023;75:15-22. PMID 36274193
  18. Messelink MA, et al. What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis. RMD Open. 2023;9:e003196. PMID 37116986
  19. Mandl P, et al. The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. Rheumatology (Oxford). 2019;58:2091-2098. PMID 31518423
  20. Michaud K, et al. Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73:1606-1616. PMID 32619340
  21. Tascilar K, et al. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Rheumatol. 2021;3:e767-e777. PMID 38297524
  22. Haschka J, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016;75:45-51. PMID 25660991
  23. van Mulligen E, et al. Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial. Ann Rheum Dis. 2020;79:1174-1181. PMID 32482645
  24. Rivellese F, et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med. 2022;28:1256-1268. PMID 35589854
  25. Kerschbaumer A, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023;82:95-106. PMID 36368906
  26. England BR, et al. 2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2023;75:1603-1615. PMID 37227116
  27. Peter WF, et al. Clinical Practice Guideline for Physical Therapist Management of People With Rheumatoid Arthritis. Phys Ther. 2021;101:pzab127. PMID 34003240
  28. Nagy G, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022;81:20-33. PMID 34407926
  29. Saavedra AA, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023 ACR/CHEST guideline. Curr Treatm Opt Rheumatol. 2024;10:43-60. PMID 39822854
  30. Fautrel B, et al. 2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis. Joint Bone Spine. 2024;91:105790. PMID 39389412
  31. Abud-Mendoza C, et al. Update of the guidelines for the pharmacological treatment of rheumatoid arthritis by the Mexican College of Rheumatology 2023. Reumatol Clin (Engl Ed). 2024;20:263-280. PMID 38796394
  32. Harigai M, et al. 2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication. Mod Rheumatol. 2025;35:387-401. PMID 39820350
  33. Conley B, et al. What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines. Clin Rheumatol. 2023;42:2267-2278. PMID 37291382
  34. Ytterberg SR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386:316-326. PMID 35081280
  35. Nagy G, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80:31-35. PMID 33004335
  36. Buch MH, et al. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17:17-33. PMID 33293696
  37. Ling SF, et al. Pharmacogenetics of methotrexate response in rheumatoid arthritis: an update. Pharmacogenomics. 2020;21:3-6. PMID 31849277